The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene APH1A (UniProt accession Q96BI3) encodes gamma-secretase subunit APH-1A (also known as Aph-1alpha or presenilin-stabilization factor) in humans (strooper2024newprecisionmedicine pages 1-2, ning2025themanipulatorbehind pages 2-4). This identity has been confirmed across multiple authoritative reviews and structural studies from 2023-2026 (odorcic2024apoandaβ46bound pages 1-2, malvankar2026theγsecretasecomplex pages 1-4, ning2025themanipulatorbehind pages 2-4). APH1A belongs to the APH-1 family and is one of two human APH-1 paralogs (APH1A and APH1B) that combine with two presenilin isoforms (PSEN1/2), nicastrin (NCT), and presenilin enhancer-2 (PEN-2/PSENEN) to generate four distinct gamma-secretase complexes in human cells (strooper2024newprecisionmedicine pages 1-2, strooper2024newprecisionmedicine pages 3-4).
APH1A is a non-catalytic scaffold protein essential for the assembly, maturation, and stabilization of the gamma-secretase complex (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4). The protein consists of seven transmembrane domains (TMDs), with the N-terminus facing the extracellular/luminal side and the C-terminus facing the cytosol (malvankar2026theγsecretasecomplex pages 6-9, odorcic2024apoandaβ46bound pages 4-5). This transmembrane architecture positions APH1A as a central structural component of the membrane-embedded protease complex.
Recent cryo-EM structural studies from 2024 have elucidated the molecular details of APH1A's interactions within the gamma-secretase complex. APH1A establishes a major interface with presenilin (PSEN1) spanning approximately 2,000 Ų, involving APH-1 transmembrane helices TM2-TM4 contacting PSEN1 TM1 and TM8-TM9 (odorcic2024apoandaβ46bound pages 2-4, odorcic2024apoandaβ46bound pages 4-5). Additionally, the C-terminus of PSEN1 inserts into the APH-1 helical bundle on the extracellular side (odorcic2024apoandaβ46bound pages 2-4). These extensive interactions provide the structural basis for APH1A's historical designation as a "presenilin-stabilization factor."
APH1A plays a central role in the stepwise assembly of the gamma-secretase complex, which occurs through the following sequence (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4):
Initial subcomplex formation: In the endoplasmic reticulum (ER), nicastrin (NCT) and APH1A first associate to form the initial subcomplex (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4).
Presenilin recruitment: The NCT-APH1A subcomplex then recruits full-length presenilin (PSEN1 or PSEN2), forming a trimeric intermediate (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4).
PEN-2 binding and activation: PEN-2/PSENEN subsequently binds, particularly interacting with PSEN transmembrane domain 4 (TMD4), which triggers presenilin autoproteolysis between TM6 and TM7, generating stable N-terminal (NTF) and C-terminal (CTF) fragments (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4).
Maturation in Golgi: The assembled complex matures in the Golgi apparatus, where nicastrin undergoes full glycosylation, before trafficking to its functional destinations (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9).
This ordered assembly process explains why APH1A is absolutely essential for gamma-secretase function—without APH1A, presenilin cannot be properly incorporated and activated within a functional complex.
While APH1A itself is not catalytic (the active site contains two aspartate residues, Asp257 and Asp385, located in PSEN1 TM6 and TM7), it significantly influences the enzyme's proteolytic properties through allosteric mechanisms (malvankar2026theγsecretasecomplex pages 6-9, strooper2024newprecisionmedicine pages 5-6). Structural studies from 2024 reveal that substrate binding induces concerted conformational rearrangements at the PSEN1/APH-1 interface, particularly involving the APH-1 TM3-TM4 loop region (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 5-7). This allosteric pathway connects substrate occupancy in the active site with structural changes propagating through PSEN1 TM1 and TM8-9 to the APH-1 interface (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 5-7).
Importantly, APH1A-containing gamma-secretase complexes differ functionally from APH1B-containing complexes. Complexes with PSEN1 and APH1A exhibit greater substrate processivity, producing relatively more short amyloid-β (Aβ) peptides compared to complexes containing PSEN2 and/or APH1B, which generate more long, aggregation-prone Aβ species (Aβ42, Aβ43) (odorcic2024apoandaβ46bound pages 1-2, strooper2024newprecisionmedicine pages 6-7). This functional difference has profound implications for Alzheimer's disease pathogenesis, as longer Aβ peptides are more prone to form toxic oligomers and amyloid plaques.
Gamma-secretase complexes containing APH1A cleave type I transmembrane proteins with short ectodomains, typically after their large extracellular domains have been removed by other proteases (ectodomain shedding) (odorcic2024apoandaβ46bound pages 1-2, hou2023theγsecretasesubstrate pages 1-4, malvankar2026theγsecretasecomplex pages 11-15). The enzyme exhibits remarkable substrate promiscuity, processing more than 145-150 different membrane proteins (hou2023theγsecretasesubstrate pages 1-4, hou2023theγsecretasesubstrate pages 4-6, malvankar2026theγsecretasecomplex pages 11-15). A 2023 unbiased substrate screen in human microglia identified 85 gamma-secretase substrates, including 59 not previously recognized, demonstrating the extensive reach of this proteolytic system (hou2023theγsecretasesubstrate pages 1-4, hou2023theγsecretasesubstrate pages 4-6).
Amyloid Precursor Protein (APP):
The processing of APP represents the most intensively studied gamma-secretase substrate, particularly due to its central role in Alzheimer's disease. After β-secretase (BACE1) cleaves APP to generate the 99-amino acid C-terminal fragment (C99), gamma-secretase performs sequential intramembrane cleavage (strooper2024newprecisionmedicine pages 5-6, strooper2024newprecisionmedicine pages 4-5, vilyaninov2024γsecretaseinthe pages 3-6, malvankar2026theγsecretasecomplex pages 15-17):
Epsilon (ε) cleavage: The initial endoproteolytic cut occurs near the cytosolic side of the membrane, releasing the APP intracellular domain (AICD) into the cytoplasm (strooper2024newprecisionmedicine pages 5-6, malvankar2026theγsecretasecomplex pages 15-17).
Sequential trimming: The remaining membrane-bound fragment undergoes progressive carboxypeptidase-like cleavages, removing 3-4 amino acids per step. This sequential processing generates two major product lines:
Recent structural studies reveal that during this process, the substrate's transmembrane helix progressively unwinds within the gamma-secretase catalytic chamber, with each cleavage step requiring reformation of a stabilizing β-sheet interaction between the substrate C-terminus and PSEN1 β-strands (strooper2024newprecisionmedicine pages 5-6, strooper2024newprecisionmedicine pages 4-5). APH1A influences this processivity through its allosteric effects on the enzyme-substrate complex stability.
Notch Receptors:
Notch signaling represents the second major gamma-secretase pathway. After ligand binding and ADAM10-mediated S2 cleavage generate the Notch extracellular truncation (NEXT), gamma-secretase performs the critical S3 cleavage within the membrane, releasing the Notch intracellular domain (NICD) into the cytosol (strooper2024newprecisionmedicine pages 1-2, malvankar2026theγsecretasecomplex pages 15-17). NICD then translocates to the nucleus where it activates transcription of Notch target genes critical for development and cell fate determination (malvankar2026theγsecretasecomplex pages 15-17). The membrane-bound remnant (Nβ) undergoes further trimming by gamma-secretase at S4 sites, similar to the sequential processing of APP (malvankar2026theγsecretasecomplex pages 15-17).
Broader Substrate Repertoire:
Beyond APP and Notch, gamma-secretase processes numerous other substrates involved in diverse cellular processes. The 2023 microglia substrate screen identified substrates including CSF1R (critical for microglial survival), TREM2 (implicated in Alzheimer's disease risk), and multiple cytokine receptors and adhesion molecules (hou2023theγsecretasesubstrate pages 1-4, hou2023theγsecretasesubstrate pages 4-6). This breadth of substrates positions APH1A-containing gamma-secretase as a central hub for regulated intramembrane proteolysis (RIP), coordinating multiple signaling pathways through irreversible proteolytic events (hou2023theγsecretasesubstrate pages 1-4).
APH1A follows a defined intracellular trafficking route as part of the gamma-secretase complex biogenesis pathway:
Endoplasmic Reticulum: Initial assembly with nicastrin occurs in the ER membrane (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4).
Golgi Apparatus: The complex matures in the Golgi, where nicastrin undergoes glycosylation and presenilin autoproteolysis is completed (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9).
Secretory Pathway: Mature complexes traffic through the secretory pathway to reach functional destinations (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9).
APH1A-containing gamma-secretase complexes are functionally active at multiple subcellular locations (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9):
Plasma Membrane: The cell surface represents a major site of gamma-secretase activity, where substrate cleavage occurs following ectodomain shedding by cell-surface proteases (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9).
Endosomal System: Complexes containing PSEN1 (which frequently pair with APH1A) cycle between the cell surface and endosomes, with significant proteolytic activity in the endosomal compartment (strooper2024newprecisionmedicine pages 3-4).
Late Endosomes/Lysosomes: Some gamma-secretase activity occurs in late endosomal and lysosomal compartments, though PSEN2-containing complexes are more enriched in these locations (strooper2024newprecisionmedicine pages 3-4).
This multi-compartmental localization enables gamma-secretase to encounter and process substrates at various stages of their trafficking through the secretory and endocytic pathways, explaining the diverse substrate repertoire.
The most critical developmental role of APH1A is in Notch signaling, a highly conserved pathway controlling cell fate decisions, proliferation, and differentiation (strooper2024newprecisionmedicine pages 1-2, malvankar2026theγsecretasecomplex pages 15-17). Genetic evidence strongly supports this function: knockout of Aph1a in mice causes lethal Notch phenotypes during embryogenesis, whereas Aph1b knockout results in only mild behavioral deficits in adulthood (strooper2024newprecisionmedicine pages 3-4). This demonstrates that APH1A is the predominant APH-1 paralog essential for canonical developmental Notch signaling.
In Alzheimer's disease pathogenesis, the specific composition of gamma-secretase complexes critically determines the length distribution of Aβ peptides produced. Recent work (2023-2024) has established that APH1A-containing complexes, particularly PSEN1/APH1A combinations, exhibit greater processivity in sequential Aβ trimming, favoring production of shorter, less aggregation-prone Aβ species (Aβ37, Aβ38, Aβ40) over longer pathogenic forms (Aβ42, Aβ43) (odorcic2024apoandaβ46bound pages 1-2, strooper2024newprecisionmedicine pages 6-7).
A landmark 2022 study demonstrated a linear correlation (R² = 0.78, p < 0.0001) between the ratio of short-to-long Aβ peptides and age of onset in familial Alzheimer's disease patients carrying PSEN1 mutations (strooper2024newprecisionmedicine pages 4-5). This finding supports a model where destabilization of the enzyme-substrate complex (as occurs with pathogenic PSEN mutations) leads to premature release of incompletely processed, longer Aβ species that seed amyloid aggregation (strooper2024newprecisionmedicine pages 5-6, strooper2024newprecisionmedicine pages 4-5). By extension, APH1A's role in stabilizing the complex and promoting processivity represents a protective influence against Alzheimer's pathogenesis.
Beyond these two major pathways, APH1A functions within a broad regulated intramembrane proteolysis (RIP) signaling network (hou2023theγsecretasesubstrate pages 1-4). The diverse substrate repertoire encompasses proteins involved in:
This network architecture positions gamma-secretase as a "signaling hub" that integrates extracellular cues into coordinated intracellular transcriptional responses through release of multiple intracellular domains (hou2023theγsecretasesubstrate pages 1-4).
The most significant recent advance is the 2024 publication of cryo-EM structures of gamma-secretase complexes containing APH-1B bound to the intermediate substrate Aβ46, without cross-linking (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 5-7). These structures, resolved at 3.3 Å for the apo complex and with substrate-bound forms, reveal:
Isoform-specific structural differences: Three non-conserved regions in APH-1 (including the TM3-TM4 loop) establish distinct contacts with PSEN1 (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 4-5).
Allosteric coupling mechanism: Substrate binding induces concerted rearrangements at the PSEN1/APH-1 interface, providing structural evidence for APH-1's allosteric modulation of substrate processing (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 5-7).
Substrate recognition determinants: New hydrogen bonding interactions between loop 1 of PSEN1 (including Tyr115) and the substrate backbone contribute to substrate stabilization during sequential cleavage (odorcic2024apoandaβ46bound pages 5-7).
These structural insights, while obtained with APH-1B, are directly informative for understanding APH1A function through comparative analysis, as APH1A-containing complexes served as the reference structures (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 2-4).
A 2023 study introduced the G-SECSI (gamma-secretase substrate identification) method, an unbiased mass spectrometry approach that identified 85 substrates in human microglia, with 59 not previously known to be gamma-secretase substrates (hou2023theγsecretasesubstrate pages 1-4, hou2023theγsecretasesubstrate pages 4-6). This work revealed that gamma-secretase processes substrates in parallel rather than sequentially, and that many substrates are involved in defining distinct microglial cell states in both homeostatic and disease conditions (hou2023theγsecretasesubstrate pages 1-4). This has important implications for understanding gamma-secretase inhibitor toxicities and for developing more targeted therapeutic approaches.
Recent reviews (2024-2026) have refined the concept of "gamma-secretase modulators" (GSMs) to distinguish a newer class of compounds termed "gamma-secretase allosteric stabilizers" (GSAS) (strooper2024newprecisionmedicine pages 6-7). Unlike earlier GSMs that primarily reduced Aβ42, GSAS compounds stabilize the enzyme-substrate complex to increase overall processivity, shifting the entire Aβ product spectrum toward shorter peptides (strooper2024newprecisionmedicine pages 6-7). This mechanism mimics the natural function of APH1A-containing complexes and acts opposite to familial Alzheimer's disease mutations.
Understanding APH1A's contribution to complex-specific properties has practical therapeutic importance: some compounds show preferential activity against APH1B- versus APH1A-containing complexes (strooper2024newprecisionmedicine pages 2-3, strooper2024newprecisionmedicine pages 6-7). Developing complex-selective inhibitors or modulators could enable targeting of specific gamma-secretase functions (e.g., in cancer) while sparing essential activities (e.g., Notch signaling), addressing the mechanism-based toxicities that have plagued broad-spectrum gamma-secretase inhibitors in clinical trials (strooper2024newprecisionmedicine pages 1-2, strooper2024newprecisionmedicine pages 2-3, strooper2024newprecisionmedicine pages 6-7).
APH1A research currently focuses on several applications:
Alzheimer's disease therapeutics: Understanding how APH1A influences Aβ processivity guides development of GSAS compounds for Alzheimer's prevention (strooper2024newprecisionmedicine pages 6-7).
Cancer therapeutics: The first gamma-secretase inhibitor (nirogacestat/Ogsiveo) received FDA approval in 2023 for desmoid tumors, validating gamma-secretase as a cancer target (strooper2024newprecisionmedicine pages 2-3). APH1A-selective approaches may enable safer cancer therapies.
Developmental biology: APH1A serves as a critical tool for dissecting Notch signaling mechanisms in embryonic development and tissue homeostasis (strooper2024newprecisionmedicine pages 3-4).
Leading researchers in the field (De Strooper, Karran, Wolfe, and others) emphasize several key points in recent authoritative reviews (strooper2024newprecisionmedicine pages 1-2, strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 1-4, strooper2024newprecisionmedicine pages 6-7):
Complexity of gamma-secretase biology: The existence of four human gamma-secretase complexes with distinct tissue distributions, subcellular localizations, and substrate preferences creates both therapeutic challenges and opportunities for selective targeting (strooper2024newprecisionmedicine pages 1-2, strooper2024newprecisionmedicine pages 3-4).
Amyloid cascade refinement: Recent evidence supports that the ratio of short-to-long Aβ peptides, rather than absolute Aβ42 levels alone, determines Alzheimer's disease risk and age of onset (strooper2024newprecisionmedicine pages 5-6, strooper2024newprecisionmedicine pages 4-5). This refines the amyloid hypothesis and validates APH1A's processivity-enhancing function as protective.
Need for complex-selective tools: The field recognizes that broad gamma-secretase inhibition causes unacceptable Notch-related toxicities; future therapeutics must achieve selectivity, potentially by targeting APH1A/B isoform differences or complex-specific regulatory proteins (strooper2024newprecisionmedicine pages 1-2, strooper2024newprecisionmedicine pages 6-7).
APH1A encodes a seven-transmembrane domain scaffold protein that is essential for gamma-secretase complex assembly, stability, and function. Its primary role is structural rather than catalytic—APH1A stabilizes presenilin and enables formation of the active protease complex. However, recent structural and functional studies reveal that APH1A also exerts allosteric effects on substrate processing, particularly influencing the processivity of sequential intramembrane cleavage. APH1A-containing complexes favor production of shorter Aβ peptides, conferring a protective influence against Alzheimer's disease pathogenesis. The protein functions at multiple subcellular locations (plasma membrane, endosomes) where it participates in processing >150 type I transmembrane substrates, including the critical APP and Notch proteins. Recent cryo-EM structures (2024) have illuminated the molecular basis of APH1A's effects through detailed characterization of PSEN1/APH-1 interfaces and substrate-induced conformational changes. Understanding APH1A's structure-function relationships continues to guide development of safer, more selective gamma-secretase therapeutics for Alzheimer's disease and cancer.
| Feature area | APH1A-specific finding | Evidence/details | Main implications | Key citation(s) |
|---|---|---|---|---|
| Identity verified | APH1A is the human gamma-secretase subunit APH-1A (Anterior pharynx-defective 1A), one of the two human APH-1 isoforms in the heterotetrameric gamma-secretase complex | Recent reviews and structural papers consistently describe four human gamma-secretase complexes generated by combinations of PSEN1/2 with APH1A/B, plus NCSTN and PSENEN/PEN-2 | Confirms the target is the human gamma-secretase scaffold subunit, not an unrelated gene symbol | (odorcic2024apoandaβ46bound pages 1-2, strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9) |
| Molecular class / primary role | APH1A is a non-catalytic, multi-pass membrane scaffold/stabilizer required for assembly and maturation of gamma-secretase | APH-1 is described as stabilizing the enzyme complex and serving as a scaffold for assembly; presenilin only becomes active after incorporation into the full complex | APH1A does not catalyze peptide bond hydrolysis itself; instead it enables formation and function of the active protease complex | (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4) |
| Membrane topology | APH1A is a 7-transmembrane-domain protein | Sequence/topology summaries in recent reviews assign APH-1 seven TMDs, with N-terminus facing the extracellular/luminal side and C-terminus facing cytosol | Topology is consistent with a structural role in the membrane-embedded core of gamma-secretase | (malvankar2026theγsecretasecomplex pages 6-9, odorcic2024apoandaβ46bound pages 4-5) |
| Key structural interfaces | APH1A forms a major membrane-embedded interface with presenilin involving APH-1 TM2-TM4 contacting PSEN1 TM1 and TM8-TM9, with insertion of the PSEN1 C-terminus into the APH-1 helical bundle on the extracellular side | The 2024 cryo-EM APH-1B study defines the conserved PSEN1/APH-1 interface and shows that isoform-specific APH-1 regions contact PSEN1 across an interface of ~2000 Ų; these data are informative for APH1A because the APH1A-bound complex is the comparison reference | Provides a structural basis for APH1A as the presenilin-stabilizing factor and as a regulator of presenilin conformational dynamics | (odorcic2024apoandaβ46bound pages 2-4, odorcic2024apoandaβ46bound pages 4-5, odorcic2024apoandaβ46bound pages 5-7) |
| Isoform-specific structural determinants | Relative to APH-1B, APH-1A differs in three non-conserved structural regions, including the TM3-TM4 loop, which is implicated in substrate-induced conformational coupling | The 2024 cryo-EM comparison shows APH-1 isoform divergence clusters in specific regions and that substrate binding propagates conformational change toward the PSEN1/APH-1 interface | Supports the idea that APH1A is not just passive scaffold but helps tune gamma-secretase conformational states and product profiles | (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 4-5, odorcic2024apoandaβ46bound pages 5-7) |
| Complex assembly step 1 | Nicastrin (NCSTN) and APH1A first form an early subcomplex in the endoplasmic reticulum | Multiple reviews describe stepwise assembly beginning with NCSTN-APH-1 association in ER membranes | APH1A nucleates early assembly of gamma-secretase biogenesis | (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4) |
| Complex assembly step 2 | The NCSTN-APH1A subcomplex recruits full-length presenilin | Presenilin joins the APH-1/NCT subcomplex before PEN-2 addition | Explains the historical alias “presenilin-stabilization factor” and APH1A’s central role in presenilin maturation | (malvankar2026theγsecretasecomplex pages 6-9, ning2025themanipulatorbehind pages 2-4) |
| Complex assembly step 3 | PEN-2/PSENEN then binds, especially via PSEN1 TMD4, triggering presenilin autoproteolysis into NTF and CTF | Reviews summarize PEN-2-dependent activation after APH-1/NCT/presenilin preassembly | APH1A supports formation of the proenzyme whose maturation yields the active gamma-secretase complex | (malvankar2026theγsecretasecomplex pages 6-9, strooper2024newprecisionmedicine pages 3-4) |
| Post-assembly maturation | Full complex matures in the Golgi, where nicastrin becomes fully glycosylated, before onward trafficking | Recent review summarizes ER dimer formation and Golgi completion/maturation | Places APH1A function in the secretory pathway during biogenesis as well as later in active complexes | (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9) |
| Contribution to catalysis | APH1A is not the catalytic subunit; catalysis occurs at PSEN1 Asp257/Asp385 within the active site | Structural reviews place the catalytic aspartates in PSEN TM6 and TM7, with APH-1 acting as a supporting subunit | APH1A affects proteolysis indirectly through complex architecture, substrate gating, and stabilization | (malvankar2026theγsecretasecomplex pages 6-9, strooper2024newprecisionmedicine pages 5-6) |
| Contribution to substrate processing | APH-1 isoforms modulate substrate processivity and the length distribution of Aβ peptides produced from APP | 2024 structural work and recent reviews note that complexes containing PSEN2 and/or APH-1B generate relatively more long, aggregation-prone Aβ species than complexes with PSEN1 and/or APH-1A | By inference, APH1A-containing complexes are associated with comparatively greater processive trimming toward shorter Aβ products | (odorcic2024apoandaβ46bound pages 1-2, strooper2024newprecisionmedicine pages 6-7) |
| Allosteric regulation | APH1A likely contributes to allosteric-like coupling between substrate binding and conformational changes in presenilin | The 2024 cryo-EM APH-1B/Aβ46 study shows substrate-induced rearrangements at the PSEN1/APH-1 interface and proposes an allosteric pathway connecting PSEN1 TM1/TM8-9 to the APH-1 TM3-TM4 loop; APH1A is the key comparator in these analyses | Strongest recent mechanistic evidence that APH1A-family proteins modulate gamma-secretase activity beyond simple assembly | (odorcic2024apoandaβ46bound pages 1-2, odorcic2024apoandaβ46bound pages 5-7) |
| Substrate class | Gamma-secretase complexes containing APH1A cleave type I transmembrane proteins, typically after ectodomain shedding and when the residual ectodomain is short | Recent reviews emphasize lack of strict sequence consensus but a common requirement for type I membrane topology and short ectodomains | Defines the biochemical context in which APH1A functions | (odorcic2024apoandaβ46bound pages 1-2, hou2023theγsecretasesubstrate pages 1-4, malvankar2026theγsecretasecomplex pages 11-15) |
| APP processing pathway | In APP processing, gamma-secretase first performs epsilon cleavage near the cytosolic leaflet to release AICD, then sequentially trims membrane-retained Aβ intermediates to shorter Aβ species | Recent reviews summarize the Aβ49→46→43→40→37 and Aβ48→45→42→38 trimming lines | APH1A’s functional importance lies in shaping processivity of this sequential intramembrane trimming reaction | (strooper2024newprecisionmedicine pages 5-6, strooper2024newprecisionmedicine pages 4-5, vilyaninov2024γsecretaseinthe pages 3-6) |
| Notch pathway role | Gamma-secretase containing APH1A cleaves Notch after ADAM-mediated S2 cleavage, releasing NICD into the cytosol/nucleus | Notch is one of the best-established substrates and a central signaling readout of gamma-secretase function | Explains why APH1A loss has strong developmental consequences and why broad gamma-secretase inhibition causes Notch-related toxicity | (strooper2024newprecisionmedicine pages 1-2, malvankar2026theγsecretasecomplex pages 15-17) |
| Breadth of substrate proteome | Gamma-secretase processes more than 145-150 substrates; a 2023 unbiased microglial substrate screen identified 85 substrates, including 59 not previously known in that context | Hou et al. developed G-SECSI and showed extensive parallel processing in human microglia | APH1A participates in a broad regulated intramembrane proteolysis network rather than a single-pathway enzyme system | (hou2023theγsecretasesubstrate pages 1-4, hou2023theγsecretasesubstrate pages 4-6, malvankar2026theγsecretasecomplex pages 11-15) |
| Subcellular localization of active function | APH1A functions in gamma-secretase complexes located in the plasma membrane and endosomal system after assembly in the ER/Golgi pathway | Reviews place mature complexes at the cell surface, endosomes, and lysosomes; super-resolution imaging confirms cell-surface gamma-secretase organization and dynamics | APH1A acts where membrane stubs of substrates encounter active gamma-secretase for intramembrane cleavage | (strooper2024newprecisionmedicine pages 3-4, malvankar2026theγsecretasecomplex pages 6-9) |
| Complex-specific trafficking context | Complexes containing PSEN1 are recycled between the cell surface and endosomes, whereas PSEN2 complexes are targeted more to late endosomes/lysosomes | De Strooper & Karran summarize compartmental differences among gamma-secretase complexes | APH1A localization depends partly on its presenilin partner; APH1A frequently participates in PSEN1 complexes with surface/endosomal activity | (strooper2024newprecisionmedicine pages 3-4) |
| Disease relevance: development | Aph1a knockout causes lethal Notch phenotypes during embryogenesis, unlike the milder phenotype of Aph1b loss | Recent review contrasts knockout phenotypes of APH1 paralogs | Indicates APH1A is the more essential APH-1 paralog for canonical developmental Notch signaling | (strooper2024newprecisionmedicine pages 3-4) |
| Disease relevance: Alzheimer’s disease | APH1A influences Aβ peptide length distribution, a core determinant of Alzheimer’s disease pathobiology, though AD-causing familial mutations are mainly in PSEN1/2, not APH1A | 2024 reviews emphasize that longer Aβ species seed aggregation; isoform composition of gamma-secretase contributes to Aβ-length bias | APH1A is mechanistically relevant to AD through complex composition and processivity, rather than as a common Mendelian AD mutation gene | (odorcic2024apoandaβ46bound pages 1-2, strooper2024newprecisionmedicine pages 4-5, strooper2024newprecisionmedicine pages 6-7) |
| Disease relevance: hidradenitis suppurativa and skin inflammation | Classical loss-of-function mutations in gamma-secretase subunits causing hidradenitis suppurativa have mostly been found in NCSTN and PSENEN, though recent dermatology reviews mention proposed APH1A/APH1B variants | Reviews distinguish AD-causing PSEN mutations from gamma-secretase haploinsufficiency syndromes affecting skin/Notch biology | Suggests APH1A may contribute to skin disease when gamma-secretase dosage/function is perturbed, but evidence is much weaker than for NCSTN/PSENEN | (strooper2024newprecisionmedicine pages 3-4, ning2025themanipulatorbehind pages 2-4) |
| Disease relevance: pharmacology / oncology | Broad gamma-secretase inhibition causes mechanism-based toxicities, but selective targeting of specific complexes is an active therapeutic goal in cancer and AD prevention research | Recent reviews note first GSI approval (nirogacestat) and discuss the need for complex-selective inhibitors/modulators; some compounds show relative selectivity for APH1B- vs APH1A-containing complexes | APH1A is a practical pharmacology discriminator for designing safer, complex-selective gamma-secretase therapeutics | (strooper2024newprecisionmedicine pages 2-3, strooper2024newprecisionmedicine pages 6-7) |
Table: This table compiles the main structural, mechanistic, localization, and disease-relevant features of human APH1A as a gamma-secretase subunit. It emphasizes recent cryo-EM and functional evidence, especially how APH1A supports assembly and modulates substrate processing.
References
(strooper2024newprecisionmedicine pages 1-2): Bart de Strooper and Eric H. Karran. New precision medicine avenues to the prevention of alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal, 43(6):887-903, Feb 2024. URL: https://doi.org/10.1038/s44318-024-00057-w, doi:10.1038/s44318-024-00057-w. This article has 40 citations.
(ning2025themanipulatorbehind pages 2-4): Gao Ning, Xing Fan, Du Juan, Zhao wenxue, Wang Sijia, Chen Meinei, Dong Xiaolong, and Qi Yiming. The manipulator behind “scissors”: γ -secretase and its modulators in alzheimer’s disease. Frontiers in Aging Neuroscience, Aug 2025. URL: https://doi.org/10.3389/fnagi.2025.1637671, doi:10.3389/fnagi.2025.1637671. This article has 4 citations and is from a peer-reviewed journal.
(odorcic2024apoandaβ46bound pages 1-2): Ivica Odorčić, Mohamed Belal Hamed, Sam Lismont, Lucía Chávez-Gutiérrez, and Rouslan G. Efremov. Apo and aβ46-bound γ-secretase structures provide insights into amyloid-β processing by the aph-1b isoform. Nature Communications, May 2024. URL: https://doi.org/10.1038/s41467-024-48776-2, doi:10.1038/s41467-024-48776-2. This article has 13 citations and is from a highest quality peer-reviewed journal.
(malvankar2026theγsecretasecomplex pages 1-4): Shweta R. Malvankar and Michael Scott Wolfe. The γ-secretase complex: from discovery to therapeutic target. RSC Chemical Biology, Jan 2026. URL: https://doi.org/10.1039/d6cb00022c, doi:10.1039/d6cb00022c. This article has 0 citations and is from a peer-reviewed journal.
(strooper2024newprecisionmedicine pages 3-4): Bart de Strooper and Eric H. Karran. New precision medicine avenues to the prevention of alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal, 43(6):887-903, Feb 2024. URL: https://doi.org/10.1038/s44318-024-00057-w, doi:10.1038/s44318-024-00057-w. This article has 40 citations.
(malvankar2026theγsecretasecomplex pages 6-9): Shweta R. Malvankar and Michael Scott Wolfe. The γ-secretase complex: from discovery to therapeutic target. RSC Chemical Biology, Jan 2026. URL: https://doi.org/10.1039/d6cb00022c, doi:10.1039/d6cb00022c. This article has 0 citations and is from a peer-reviewed journal.
(odorcic2024apoandaβ46bound pages 4-5): Ivica Odorčić, Mohamed Belal Hamed, Sam Lismont, Lucía Chávez-Gutiérrez, and Rouslan G. Efremov. Apo and aβ46-bound γ-secretase structures provide insights into amyloid-β processing by the aph-1b isoform. Nature Communications, May 2024. URL: https://doi.org/10.1038/s41467-024-48776-2, doi:10.1038/s41467-024-48776-2. This article has 13 citations and is from a highest quality peer-reviewed journal.
(odorcic2024apoandaβ46bound pages 2-4): Ivica Odorčić, Mohamed Belal Hamed, Sam Lismont, Lucía Chávez-Gutiérrez, and Rouslan G. Efremov. Apo and aβ46-bound γ-secretase structures provide insights into amyloid-β processing by the aph-1b isoform. Nature Communications, May 2024. URL: https://doi.org/10.1038/s41467-024-48776-2, doi:10.1038/s41467-024-48776-2. This article has 13 citations and is from a highest quality peer-reviewed journal.
(strooper2024newprecisionmedicine pages 5-6): Bart de Strooper and Eric H. Karran. New precision medicine avenues to the prevention of alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal, 43(6):887-903, Feb 2024. URL: https://doi.org/10.1038/s44318-024-00057-w, doi:10.1038/s44318-024-00057-w. This article has 40 citations.
(odorcic2024apoandaβ46bound pages 5-7): Ivica Odorčić, Mohamed Belal Hamed, Sam Lismont, Lucía Chávez-Gutiérrez, and Rouslan G. Efremov. Apo and aβ46-bound γ-secretase structures provide insights into amyloid-β processing by the aph-1b isoform. Nature Communications, May 2024. URL: https://doi.org/10.1038/s41467-024-48776-2, doi:10.1038/s41467-024-48776-2. This article has 13 citations and is from a highest quality peer-reviewed journal.
(strooper2024newprecisionmedicine pages 6-7): Bart de Strooper and Eric H. Karran. New precision medicine avenues to the prevention of alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal, 43(6):887-903, Feb 2024. URL: https://doi.org/10.1038/s44318-024-00057-w, doi:10.1038/s44318-024-00057-w. This article has 40 citations.
(hou2023theγsecretasesubstrate pages 1-4): Pengfei Hou, Magdalena Zielonka, Lutgarde Serneels, Anna Martinez-Muriana, Nicola Fattorelli, Leen Wolfs, Suresh Poovathingal, Dries T'Syen, Sriram Balusu, Tom Theys, Mark Fiers, Renzo Mancuso, Andrew J.M. Howden, and Bart De Strooper. The γ-secretase substrate proteome and its role in cell signaling regulation. Molecular cell, 83 22:4106-4122.e10, Nov 2023. URL: https://doi.org/10.1016/j.molcel.2023.10.029, doi:10.1016/j.molcel.2023.10.029. This article has 27 citations and is from a highest quality peer-reviewed journal.
(malvankar2026theγsecretasecomplex pages 11-15): Shweta R. Malvankar and Michael Scott Wolfe. The γ-secretase complex: from discovery to therapeutic target. RSC Chemical Biology, Jan 2026. URL: https://doi.org/10.1039/d6cb00022c, doi:10.1039/d6cb00022c. This article has 0 citations and is from a peer-reviewed journal.
(hou2023theγsecretasesubstrate pages 4-6): Pengfei Hou, Magdalena Zielonka, Lutgarde Serneels, Anna Martinez-Muriana, Nicola Fattorelli, Leen Wolfs, Suresh Poovathingal, Dries T'Syen, Sriram Balusu, Tom Theys, Mark Fiers, Renzo Mancuso, Andrew J.M. Howden, and Bart De Strooper. The γ-secretase substrate proteome and its role in cell signaling regulation. Molecular cell, 83 22:4106-4122.e10, Nov 2023. URL: https://doi.org/10.1016/j.molcel.2023.10.029, doi:10.1016/j.molcel.2023.10.029. This article has 27 citations and is from a highest quality peer-reviewed journal.
(strooper2024newprecisionmedicine pages 4-5): Bart de Strooper and Eric H. Karran. New precision medicine avenues to the prevention of alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal, 43(6):887-903, Feb 2024. URL: https://doi.org/10.1038/s44318-024-00057-w, doi:10.1038/s44318-024-00057-w. This article has 40 citations.
(vilyaninov2024γsecretaseinthe pages 3-6): Vladimir N. Vilyaninov, Vladimir I. Vashchenko, and Petr D. Shabanov. Γ-secretase in the pathogenesis of alzheimer’s disease and therapeutic potential of its modulators. Psychopharmacology & biological narcology, 15:211-236, Oct 2024. URL: https://doi.org/10.17816/phbn635851, doi:10.17816/phbn635851. This article has 0 citations.
(malvankar2026theγsecretasecomplex pages 15-17): Shweta R. Malvankar and Michael Scott Wolfe. The γ-secretase complex: from discovery to therapeutic target. RSC Chemical Biology, Jan 2026. URL: https://doi.org/10.1039/d6cb00022c, doi:10.1039/d6cb00022c. This article has 0 citations and is from a peer-reviewed journal.
(strooper2024newprecisionmedicine pages 2-3): Bart de Strooper and Eric H. Karran. New precision medicine avenues to the prevention of alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal, 43(6):887-903, Feb 2024. URL: https://doi.org/10.1038/s44318-024-00057-w, doi:10.1038/s44318-024-00057-w. This article has 40 citations.